Human isotope fractional absorption studies comparing chelated Magnesium Glycinate vs. Citrate vs. 4% Oxide, CYP2R1/CYP27B1 magnesium-dependent Vitamin D3 activation trials, and Metformin-induced Vitamin B12 holotranscobalamin depletion. Explore 4,327 indexed studies and multi-trial syntheses with verified PubMed PMIDs, participant sample sizes (N), and Absolute vs. Relative Risk numbers.
The Plain-English Receipt: Only 1.2% of prediabetic adults on Tirzepatide progressed to Type 2 diabetes over 3.4 years vs. 19.3% on placebo (Absolute Risk Reduction = 18.1% • Number Needed to Treat = 6).
Maternal vaccination with RSVpreF in pregnant women at 32-36 weeks of gestation is safe and efficacious against RSV-associated lower breathing tract illness in infants to 6 months.
CONCLUSION: This meta-analysis identified several risk factors associated with AGA presence and progression, including a family history of AGA, smoking, alcohol consumption, insufficient or poor-quality sleep,...
This NMR score seemed promising for DLBCL risk stratification, even among responder patients after R-CHOP treatment.
In a difficult-to-treat population with OA, fasinumab 1 mg Q4W achieved clinically meaningful improvements by week 16 versus placebo and naproxen.
Vitamin D supplementation was associated with increased circulating 25(OH)D concentrations, whereas current evidence is insufficient to support a consistent improvement in physical performance. Given the low to very low certainty of evidence, these findings should be interpreted cautiously.
Our results showed that higher doses and more frequent IVIG/fSCIG 10% administration were associated with a lower mean probability of increased adjusted INCAT score (i.e., lower probability of relapse), remaining < 50% in all...
Perfluorohexyloctane eye drops improved signs and symptoms of DED associated with MGD and were safe in both postmenopausal and premenopausal women.
Treatment-related ALC decline is an independent adverse prognostic factor in LA-HNSCC.
PR-RBCs contained 5.2% less Hb (mean [SD] Test 58.1 [6.5] g; Control 61.5 [6.8] g Hb, p < .001) due to manufacturing volume losses.
This intervention has the potential to significantly influence current treatment strategies for AE-IPF.
Chronic irAEs can negatively affect HRQoL, mental health, and the ability to work.
HRQoL improved with tirzepatide and semaglutide, with greater improvement in GH with tirzepatide, especially in participants with limited baseline physical function.
Real-world benefits and safety profiles were comparable for Chinese children with GHD treated with somapacitan or daily GH.
All the treatments were well tolerated overall.
No significant imaging findings necessitating surgery were observed, suggesting that chemonucleolysis with condoliase remains a safe and effective treatment option for LDH over the long term.
The predicted steady-state how the body absorbs the medicine parameters (C max , C avg , and C trough ) of once-monthly TV-44749 doses of 318, 425, and 531 mg were comparable to daily oral doses of 10, 15, and 20 mg, respectively.
The original clinical trials were registered at ClinicalTrials.gov under the identifiers NCT04767581, NCT04766398, and NCT04766385.
In this selected Canadian post-trial continuation cohort, osilodrostat was associated with rapid initial biochemical control and durable long-term control in many patients for up to 10 years.
Lower baseline PF was associated with a higher prevalence of ORCs.
Tirzepatide was associated with numerically greater weight loss across available studies, though high heterogeneity and observational data limit causal inference.
E In conclusion, abaloparatide improved measured properties in men with osteoporosis on acetabular and femoral sides of the hip joint, increasing acetabular BMD and improving femur strength.
Xeligekimab provides rapid symptom resolution across all clinical dimensions, high and sustained achievement of treatment targets, and comprehensive restoration of quality of life.
Anti-SARS-CoV-2 antibodies at baseline, more common with placebo, provided protection against poor clinical outcomes.
Further long-term, large-scale studies are recommended to confirm this evidence.
These findings on the pharmacology of VOS underscore the importance of rapidly restoring key protective functions of the microbiome in patients with recurrent CDI to achieve durable prevention of recurrence, as observed in the...
Ivarmacitinib provides rapid and continuous improvement across all anatomical regions in patients with moderate-to-severe AD.
Lobeglitazone as an add-on to empagliflozin and metformin significantly improved glycaemic control in patients with T2DM inadequately controlled on metformin and empagliflozin dual therapy.
RFX treatment reduced microbial richness and decreased the abundance of taxa typically enriched in advanced cirrhosis (e.g., Escherichia , Streptococcus , Veillonella ).
Insulin needs decrease rapidly upon initiation of semaglutide use in type 1 diabetes on pump therapy, predominantly due to bolus changes from less carbohydrate consumption.
The patient-reported outcomes also improved sustainedly.
Traditional health headlines often exaggerate findings by reporting only Relative Risk Reduction—for example, claiming a drug cuts risk by 50% when the event rate dropped from 2% to 1% (an Absolute Risk Reduction of just 1.0 percentage point, meaning 100 patients must take the drug for 1 person to benefit, or NNT = 100). On dotMD, every flagship study breakdown reports both Relative Risk and Absolute Risk alongside the exact sample size (N) and trial duration.
Every study on dotMD displays its exact Study Design Tier at the top of the card (Phase 3 Randomized Trial, Randomized Controlled Trial, Meta-Analysis & Systematic Review, Multi-Trial Clinical Evidence Synthesis, Journal Watch Cohort, or FDA Safety Alert) along with the human participant count (N). Preclinical mouse or cell-culture data is never presented as human clinical proof.
Arbitrary 0-to-100 rigor scores obscure what actually makes a study trustworthy. Instead of synthetic scores, dotMD surfaces the verifiable primary evidence signals: exact NCBI PubMed IDs (PMID), ClinicalTrials.gov registration numbers (NCT), double-blind vs. crossover design, sample size (N), p-values / Hazard Ratios, and study limitations.
Medical research is only useful if you can act on it safely with your clinician. Every flagship research synthesis links directly to the parent Condition diagnostic cutoff guide, the Medication FDA DailyMed & CMS NADAC wholesale price ledger, the Supplement elemental weight decoder, and our High-CPT-Volume Specialist Directory.
